Smithfield Trust Co Sells 408 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Smithfield Trust Co reduced its position in IQVIA Holdings Inc. (NYSE:IQV) by 59.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 274 shares of the medical research company’s stock after selling 408 shares during the period. Smithfield Trust Co’s holdings in IQVIA were worth $54,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Capital Performance Advisors LLP bought a new position in IQVIA during the 3rd quarter valued at $27,000. Synergy Asset Management LLC bought a new position in IQVIA during the 4th quarter valued at $33,000. Avior Wealth Management LLC lifted its stake in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 87 shares in the last quarter. Assetmark Inc. lifted its stake in IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 196 shares in the last quarter. Finally, Ashton Thomas Securities LLC bought a new position in IQVIA during the 3rd quarter valued at $57,000. 89.62% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

IQV has been the subject of several research analyst reports. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a research report on Tuesday. Barclays decreased their target price on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. BTIG Research lowered IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Stephens initiated coverage on IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 target price for the company. Finally, William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Stock Up 1.3 %

IQV stock opened at $186.04 on Thursday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market capitalization of $32.80 billion, a PE ratio of 24.81, a PEG ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a twelve month low of $179.28 and a twelve month high of $261.73. The stock has a 50-day simple moving average of $198.24 and a two-hundred day simple moving average of $213.66.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.